Register
Community
Physicians
Editors
Experts
Code of conduct
Blog
Company
About
Publications
Press
Careers
Programs
Journal Club
Targeted Topic
Clinical Trial
Tumor Board
Contact Us
Sign in
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
Liver and Pancreas Tumors
What is your approach to locally advanced pancreatic cancer that has not progressed after neoadjuvant chemotherapy +/- chemoradiation but remains unresectable?
Related Questions
What clinical parameters determine when you treat a large HCC lesion with ablative radiation vs Y-90?
What systemic therapy would you offer for a local, unresectable relapse of a mixed acinar neuroendocrine carcinoma of the pancreas?
Given the updated results of the PREOPANC study, how can gemcitabine-based neoadjuvant chemoradiation be best incorporated into the treatment of resectable or borderline resectable pancreatic cancer?
What is your approach to patients with unresectable, node-negative perihilar cholangiocarcinoma who have undergone biliary stenting and have no evidence of distant disease?
How do you approach management of non-resectable periampullary adenocarcinoma in an elderly patient with otherwise good PS?
Based on the TOPAZ-1 study, do you routinely include durvalumab in first line treatment of advanced bile duct cancer?
How does data from the HIMALAYA trial impact your first line treatment selection for advanced HCC?
Would you prioritize TACE or systemic therapy in BCLC B multifocal HCC with tumor bulk higher than "up to 7?"
Is there a role for liver transplantation in an initially unresectable HCC with a complete response after bevacizumab-atezolizumab?
What, if any, role does systemic therapy have in the treatment of HCC amenable to definitive locoregional therapy?
